
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.



